Ubenimex
An aminopeptidase inhibitor used in cancer research
| Ubenimex | |
|---|---|
|
| |
| Chemical nomenclature | |
| IUPAC name | (2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl-L-leucine
|
Ubenimex, also known as bestatin, is a potent inhibitor of aminopeptidases, a class of enzymes that play a role in the degradation of proteins. It is primarily used in research settings to study its effects on cancer and immune system modulation.
Discovery and Development[edit]
Ubenimex was first isolated from the culture broth of the bacterium Streptomyces olivoreticuli. The compound was identified as a potent inhibitor of aminopeptidase B and leucine aminopeptidase, enzymes involved in protein metabolism. Its discovery has led to extensive research into its potential therapeutic applications, particularly in oncology.
Mechanism of Action[edit]
Ubenimex functions by inhibiting aminopeptidases, which are enzymes that remove amino acids from the amino terminus of proteins and peptides. By inhibiting these enzymes, ubenimex can interfere with the breakdown of proteins, potentially affecting various cellular processes. This mechanism is thought to contribute to its effects on tumor growth and immune response.
Clinical Applications[edit]
While ubenimex has shown promise in preclinical studies, its clinical applications are still under investigation. It has been studied for its potential use in treating various types of cancer, including leukemia and lung cancer. Additionally, ubenimex has been explored for its immunomodulatory effects, which could make it useful in treating autoimmune diseases and enhancing immune responses.
Research and Studies[edit]
Numerous studies have been conducted to evaluate the efficacy and safety of ubenimex in different therapeutic contexts. In cancer research, it has been tested in combination with other chemotherapeutic agents to assess its ability to enhance treatment outcomes. Research has also focused on its role in modulating the immune system, with some studies suggesting it may enhance the activity of natural killer cells and T cells.
Related Pages[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian